PURPOSE: In this case report, we describe 7 patients with suboptimal dosimetry after (125)I prostate brachytherapy who underwent a second implant procedure to improve the dosimetric coverage of the prostate. METHODS AND MATERIALS: Seven patients underwent second (125)I implants for suboptimal dosimetry after their initial implant for prostate cancer. The pretreatment characteristics (clinical stage, Gleason score, initial prostate-specific antigen level, location of positive cores, International Prostate Symptom Score, potency, use of androgen suppression, initial implant planning characteristics) were noted. The "Day 30" CT-based dosimetry parameters after the first implant and "Day 0" CT-based dosimetry after the reimplant were recorded (volumes of prostate and rectum covered by 100% and 150% of the dose and dose covering 90% of the prostate volume). The toxicity of the second procedure, International Prostate Symptom Scores before and after reimplantation, the clinical course, and prostate-specific antigen outcomes after reimplant were examined. We described our reimplant planning and intraoperative procedure. RESULTS: In all 7 patients, we were able to achieve very favorable dosimetry after the second procedure. The acute toxicity of the reimplant procedure was reasonably low, and the short-term prostate-specific antigen outcome has been favorable. CONCLUSION: It is possible to add more seeds safely to the dosimetrically cool area after the initial brachytherapy procedure and achieve excellent postimplant dosimetry with acceptable acute toxicity. The ultimate benefits and long-term toxicity of reimplantation are unknown.
PURPOSE: In this case report, we describe 7 patients with suboptimal dosimetry after (125)I prostate brachytherapy who underwent a second implant procedure to improve the dosimetric coverage of the prostate. METHODS AND MATERIALS: Seven patients underwent second (125)I implants for suboptimal dosimetry after their initial implant for prostate cancer. The pretreatment characteristics (clinical stage, Gleason score, initial prostate-specific antigen level, location of positive cores, International Prostate Symptom Score, potency, use of androgen suppression, initial implant planning characteristics) were noted. The "Day 30" CT-based dosimetry parameters after the first implant and "Day 0" CT-based dosimetry after the reimplant were recorded (volumes of prostate and rectum covered by 100% and 150% of the dose and dose covering 90% of the prostate volume). The toxicity of the second procedure, International Prostate Symptom Scores before and after reimplantation, the clinical course, and prostate-specific antigen outcomes after reimplant were examined. We described our reimplant planning and intraoperative procedure. RESULTS: In all 7 patients, we were able to achieve very favorable dosimetry after the second procedure. The acute toxicity of the reimplant procedure was reasonably low, and the short-term prostate-specific antigen outcome has been favorable. CONCLUSION: It is possible to add more seeds safely to the dosimetrically cool area after the initial brachytherapy procedure and achieve excellent postimplant dosimetry with acceptable acute toxicity. The ultimate benefits and long-term toxicity of reimplantation are unknown.
Authors: Junghoon Lee; Christian Labat; Ameet K Jain; Danny Y Song; Everette Clif Burdette; Gabor Fichtinger; Jerry L Prince Journal: IEEE Trans Med Imaging Date: 2010-07-19 Impact factor: 10.048
Authors: Michael J Zelefsky; Gil'ad N Cohen; Walter R Bosch; Lisa Morikawa; Najma Khalid; Cheryl L Crozier; W Robert Lee; Anthony Zietman; Jean Owen; J Frank Wilson; Phillip M Devlin Journal: Brachytherapy Date: 2012-07-21 Impact factor: 2.362
Authors: T Shaikh; N G Zaorsky; K Ruth; D Y Chen; R E Greenberg; J Li; K Crawford; E M Horwitz Journal: Brachytherapy Date: 2014-11-07 Impact factor: 2.362
Authors: Junghoon Lee; Nathanael Kuo; Anton Deguet; Ehsan Dehghan; Danny Y Song; Everette C Burdette; Jerry L Prince Journal: Phys Med Biol Date: 2011-07-19 Impact factor: 3.609
Authors: Tanmay Singh; Junghoon Lee; Marianna Zahurak; Hee Joon Bae; Tamey Habtu; Robert Hobbs; Yi Le; Everette C Burdette; Daniel Y Song Journal: Pract Radiat Oncol Date: 2021-03-13
Authors: Laura Doyle; Adam J Hesney; Katherine L Chapman; Haisong Liu; Perry R Weiner; Adam P Dicker; Yan Yu; Timothy N Showalter Journal: J Contemp Brachytherapy Date: 2012-09-29
Authors: Paul Martin Putora; Ludwig Plasswilm; Wolf Seelentag; Johann Schiefer; Patrick Markart; Hans-Peter Schmid; Daniel Engeler Journal: Radiat Oncol Date: 2013-08-06 Impact factor: 3.481